People: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

99.98USD
4:00pm EDT
Change (% chg)

$-0.06 (-0.06%)
Prev Close
$100.04
Open
$99.85
Day's High
$100.24
Day's Low
$99.11
Volume
2,608,164
Avg. Vol
2,472,487
52-wk High
$109.49
52-wk Low
$95.10

Search Stocks

Stoffels, Paulus 

Dr. Paulus Stoffels is Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group of Johnson & Johnson. He joined the Company in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec. In 2005, he was appointed Company Group Chairman, Global Virology where he led the development of PREZISTA® and INTELENCE®, leading products for the treatment of HIV. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the Central Nervous System and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals, in 2009, and in 2011 became Worldwide Chairman, Pharmaceuticals, with responsibility for the Company's therapeutic pipeline through global research and development and strategic business development. In 2012, Dr. Stoffels was also appointed Chief Scientific Officer, with responsibility for enterprise-wide innovation and product safety, and a Member of the Executive Committee.

Basic Compensation

Total Annual Compensation, USD 3,648,870
Restricted Stock Awards, USD 10,690,500
Long-Term Incentive Plans, USD --
All Other, USD 3,999,920
Fiscal Year Total, USD 18,339,300

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 53,168 1,408,270.00
Name Fiscal Year Total

Alex Gorsky

24,989,300

Dominic Caruso

10,349,000

Sandra Peterson

7,086,610

Paulus Stoffels

18,339,300

Michael Ullmann

5,960,690

Peter Fasolo

3,621,280
As Of  27 Dec 2014
Search Stocks